Hims shares logged their best session in a month and added after-hours gains. ・Novo expanded oral Wegovy access, while Citi kept a ‘Sell’ rating on Hims. ・Hims continues to broaden its platform ...

Hims Weight Loss offers personalized clinical programs with GLP-1 injections, medication management, and ongoing support.

Hims & Hers Health, Inc. faces short-term pressure after missing Novo’s partner list, but lab testing boosts long-term growth ...

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the Stocks With Huge Catalysts on the Horizon. On July 9, Hims & Hers Health, Inc. (NYSE:HIMS) announced expanding into Canada with a new affordable ...

This post is brought to you in paid partnership with Hims. We’re one week into the new year. By now, the initial burst of ...

MOBILE, Ala. (WALA) - More than 40% of American adults live with obesity, yet personalized, supportive care is often out of reach due to challenges like soaring costs, lack of insurance coverage, or ...

Hims & Hers HIMS recently announced that it is expanding access to its comprehensive Weight Loss Program to customers in the United Kingdom. The company is launching its Hers platform to provide ...

Hims & Hers is down 30% but still a Buy: margin expansion, GLP-1 clarity, new hormone care, and global growth. Learn more about HIMS stock here.

(RTTNews) - Hims & Hers Health, Inc. (HIMS), a health and wellness platform, on Monday announced that its board has authorized a new share repurchase program of up to $250 million in Class A common ...

Hims & Hers Health Inc (NYSE:HIMS) shares surged in early trading Wednesday before pulling back. The stock was still up marginally at last check after the company announced a planned Canadian ...

One of the more popular ideas floating around on Wall Street, Hims & Hers Health Inc (NYSE:HIMS) has largely benefited from the general ascendancy of the telehealth business model, along with strong ...